Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
MWN-AI** Summary
Valneva SE, a French specialty vaccine company, announced its participation in the 26th World Vaccine Congress, taking place from March 31 to April 2, 2026, at the Walter E. Washington Convention Center in Washington, D.C. The event will feature a presentation by Susanne Eder-Lingelbach, Vice President of Clinical Development, discussing "Vaccine Development updates for chikungunya – Phase IV and real-world evidence studies." This presentation comes on the heels of Valneva and its partner, Instituto Butantan, launching a pilot campaign in Brazil for their single-shot chikungunya vaccine, IXCHIQ®. Over 12,000 vaccinations have been conducted as part of this initiative, aimed at assessing the vaccine's real-world effectiveness and safety.
Additionally, on April 1, Valneva’s Chief Medical Officer, Dr. Juan Carlos Jaramillo, will participate in a panel discussing mosquito-borne vaccines, alongside experts from the Coalition for Epidemic Preparedness Innovations and the Ministry of Health in Kenya. The conference serves as an opportunity for Valneva to engage with current and potential partners, with a dedicated booth in the exhibition area.
Chikungunya virus, endemic in over 110 countries, is a mosquito-borne illness causing debilitating symptoms such as fever and severe joint pain. The global prevalence of chikungunya has increased significantly since 2004, prompting health authorities like the WHO to identify it as a major public health concern.
Valneva focuses on developing vaccines for infectious diseases and boasts a portfolio that includes the only Lyme disease vaccine candidate in advanced development, partnered with Pfizer. The company leverages its expertise to drive vaccine innovation in response to pressing global health needs. For more information, visit Valneva's website.
MWN-AI** Analysis
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) presents intriguing investment opportunities in light of its strategic participation in the upcoming 26th World Vaccine Congress from March 31 to April 2, 2026, in Washington, D.C. The company is highlighting its innovative chikungunya vaccine IXCHIQ®, which has already seen an impressive rollout in Brazil, with over 12,000 vaccinations, feeding into its post-marketing studies. This proactive engagement not only enhances Valneva's visibility in the public health sector but reinforces its commitment to addressing significant unmet medical needs.
The chikungunya virus (CHIKV) represents a burgeoning global health crisis, particularly as climate change facilitates the spread of the Aedes mosquito vectors. With the World Health Organization flagging it as a major public health issue, Valneva’s endeavors can strategically position the company as a leader in the vaccine space. The presentations and discussions at the congress will not only enhance Valneva’s scientific credibility but are likely to attract collaboration opportunities with various health organizations, including potential partnerships similar to its ongoing collaboration with Instituto Butantan.
Investors should closely monitor developments during and post-conference, particularly regarding updates on IXCHIQ® and potential new partnerships that could arise. Given Valneva's existing vaccines and its pipeline, including candidates against Lyme disease and Shigella, the company's growth trajectory appears promising, bolstered by increasing international health threats and funding frameworks like Horizon Europe and CEPI.
However, investors should remain cognizant of inherent risks—especially around regulatory hurdles and market competition. As such, while there is potential for growth through strategic involvement in global health discussions, the stock may exhibit volatility. A cautiously optimistic approach, with a watchful eye on upcoming clinical results and partnership announcements, is recommended for stakeholders interested in Valneva.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its participation in the upcoming 26th World Vaccine Congress, which will take place from March 31 to April 2, 2026 at the Walter E. convention center in Washington, D.C. Led by the Company´s Chief Executive Officer, Thomas Lingelbach, a team of Valneva´s senior executives will participate in multiple events throughout the conference.
On April 1, 2026, at 9:40 am EST, Susanne Eder-Lingelbach, Vice President Clinical Development at Valneva, will present “Vaccine Development updates for chikungunya – Phase IV and real-world evidence studies".
Valneva and its partner Instituto Butantan recently announced the launch of a pilot vaccination campaign with Valneva’s single shot chikungunya vaccine IXCHIQ® in Brazil, which will serve as the basis for post-marketing commitment studies. Over 12,000 people have already been vaccinated as part of this campaign which evaluates the effectiveness and safety of IXCHIQ® in a real-world setting.
On the same day at 9:55 am EST, Valneva’s Chief Medical Officer, Dr. Juan Carlos Jaramillo, will take part in the “chikungunya and mosquito-borne vaccines: bridging outbreak response, manufacturing and market creation” panel discussion alongside Dr Mandeep Singh Dhingra, Head of R&D Programs at the Coalition for Epidemic Preparedness Innovations, Mary Magubo, Head of Advocacy Communication at the Ministry of Health Kenya, and moderated by Sushant Sahastrabuddhe, Deputy Director General, International Vaccine Institute.
The Company will also use the event as an opportunity to meet with current and potential partners. It will have a presence in the exhibition area at booth #538.
About Chikungunya
Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can persist for weeks to years1. In 2004, the disease began to spread quickly, causing large-scale outbreaks around the world. Since the re-emergence of the virus, CHIKV has now been identified in over 110 countries in Asia, Africa, Europe and the Americas2. Between 2013 and 2023, more than 3.7 million cases were reported in the Americas3 and the economic impact is considered to be significant. The medical and economic burden is expected to grow with climate change as the mosquito vectors that transmit the disease continue to spread geographically. As such, the World Health Organization (WHO) has highlighted chikungunya as a major public health problem.4
About Valneva SE
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.
Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com.
About CEPI
CEPI was launched in 2017 as an innovative partnership between public, private, philanthropic and civil organizations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic disease threats and enable equitable access to them. CEPI has supported the development of more than 70 vaccine candidates or platform technologies against multiple known high-risk pathogens and is advancing the development of rapid response platforms for vaccines against a future Disease X. Central to CEPI’s pandemic-beating five-year plan for 2022-2026 is the ‘100 Days Mission’ to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days.
About Horizon Europe
Horizon Europe — #HorizonEU — is the European Union's flagship Research and Innovation programme, part of the EU-long-term Multiannual Financial Framework (MFF) with a budget of €95.5 billion to spend over a seven-year period (2021-2027). Under Horizon Europe, health research will be supported with the aim of finding new ways to keep people healthy, prevent diseases, develop better diagnostics and more effective therapies, use personalized medicine approaches to improve healthcare and wellbeing, and take up innovative health technologies, such as digital ones.
Media and Investor Relations Contacts
Laetitia Bachelot-Fontaine VP Global Communications & European Investor Relations M +33 (0)6 4516 7099 laetitia.bachelot-fontaine@valneva.com Joshua Drumm, Ph.D. VP Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com
Forward-Looking Statements
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to business partnerships and the progress, timing, results and completion of technology transfer and regulatory approvals in additional markets. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press
release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise
Attachment
FAQ**
How does Valneva SE INRLF plan to leverage insights gained from the 26th World Vaccine Congress to enhance its vaccine development strategies, particularly regarding chikungunya and other infectious diseases?
Given the promising results from the Brazil pilot vaccination campaign, what are the next steps for Valneva SE INRLF in terms of post-marketing commitment studies for the IXCHIQ® vaccine?
In light of the increasing economic impact of chikungunya and climate change, how does Valneva SE INRLF intend to address potential challenges in vaccine distribution and efficacy in affected regions?
What partnerships is Valneva SE INRLF seeking to establish during the World Vaccine Congress to accelerate the development and deployment of its vaccine candidates?
**MWN-AI FAQ is based on asking OpenAI questions about Valneva SE (OTC: INRLF).
NASDAQ: INRLF
INRLF Trading
0.0% G/L:
$2.74 Last:
100 Volume:
$2.74 Open:
